Press Releases Incyte Corporation

Equities

INCY

US45337C1027

Market Closed - Nasdaq Other stock markets 21:00:00 31/05/2024 BST			5-day change	1st Jan Change
57.79 ^USD	+0.86%		+0.84%	-7.96%

05-23	Deutsche Bank Initiates Incyte to Hold Rating With $55 Price Target	MT
05-21	Incyte Acquires 2 Office Buildings in Delaware	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Incyte Completes Acquisition of Escient Pharmaceuticals	05-30	BU
Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings	05-21	BU
Incyte to Present at Upcoming Investor Conference	05-21	BU
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress	05-14	BU
Incyte, Squarespace rise; Chimera Investment, Amazon fall, Monday, 5/13/2024	05-13	AQ
Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock	05-13	BU
Incyte to Present at Upcoming Investor Conference	05-02	BU
Incyte: Q1 Earnings Snapshot	04-30	AQ
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs	04-30	BU
'Shadow Trading' Verdict A Reminder For Companies To Review Insider Trading Policies And Train Insiders	04-29	AQ
SEC Secures Groundbreaking Win In Shadow Trading Insider Trading Case	04-28	AQ
"Shadow Trading" Is Insider Trading: Jury Establishes Liability In Historic Shadow Trading Case	04-24	AQ
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists	04-23	BU
SEC Wins Novel 'Shadow Trading' Trial Against Biopharma Executive	04-23	AQ
Incyte to Report First Quarter Financial Results	04-11	BU
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(4) - March 29, 2024	04-01	AQ
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia	04-01	BU
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	03-29	BU
SEC v Panuwat: The SEC's Novel "Shadow Trading" Insider Trading Case Goes To Trial	03-19	AQ
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis	03-10	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Incyte Corporation : Is a big change imminent?

October 26, 2023 at 03:00 pm